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mount importance is the requirement to keep public health care at
the highest scientific level, based on evidence and medical
competence.
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Risk–benefit analysis should be the only basis for approval or reg-
istration of a new agent. However in addition to this, in Sweden,
for example, there is an obligation to promote cost-effective use
of drugs based on written information or workshops that include
subscribers. The National Institute of Clinical Excellence (NICE), a
special health authority of the British National Health Service,
deals with issues of cost and reimbursement. Regulators may
think of considering cost effectiveness when they request data
to substantiate efficacy of new anticancer agents as long as
patients are provided with best possible treatment. If, however,
society is not prepared to pay for new products, then they should
not be developed.
The goal of regulators is to limit unnecessary queries because
they needlessly increase the price of new drugs. A tradeoff exists
between quality of data and cost and data quality cannot be
lowered below some point. Industry dislikes segmented pricing,
but, particularly in the case of drug combinations, costs are pro-
hibitive for many countries. Differential pricing, based on the
region where a drug is being marketed, is one way to maximise
income. Regulatory authorities should take this factor into
account as they consider registering or licensing new anticancer
therapies.
Oncology involves a very special group of drugs. Is a new drug
development model for oncology drugs required to get them to
the market more quickly? Is conditional or accelerated approval
the best means to do so? In theory, conditional approval should
work although it is a relatively new process. Linking conditional
approval to conditional reimbursement, however, needs to be
very carefully evaluated as it should be possible to reassess the
cost–benefit of a conditionally approved therapy and take it off
the market if the cost–benefit analysis is not favourable (although
it would be a very difficult situation).
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This discussion on pharmacoeconomics involves not only indus-
try and academia, but also real people who have cancer. Some
people are treated and cured, but many have to live with the dis-
ease. Results of a keypad voting survey1 regarding the patient
access to anticancer therapy of 104 cancer advocates in May
2005 are shown in Table 1.
Interestingly, 100% of respondents from France indicated they
knewof no onewhohad been refused access to a cancer treatment
because of cost, whereas 100% of those from Poland responded
that they did. Clearly, cost is a factor, and the ability to access
new anticancer therapies varies greatly across Europe. Patients
do not think like consumers, though, because they do not care
about price; they just want the best treatment.
Therefore the question is that if a significant number of people
in Europe are not able to access technologies, what is the point of
developing or testing them? To ensure that real people can benefit
from new drugs means eliminating barriers to access, which
include the high price tag of the drugs and the time it takes for
registration or licensure. Clinical trials, regulatory agency review
and health technology assessments (HTAs) all take time, but
patients with life-threatening disease often do not have that
luxury.
The goals of new-drug development should be to provide
patients everywhere with timely access to safe and effective ther-
apies and to ensure that patients are not put at undue risk by tak-
ing innovative medicines. Thanks to the informed consent
process, patients understand risk and many are willing to accept
it by participating in clinical trials, even if they might not benefit
directly. Nevertheless, placebo-controlled trials present chal-
lenges because patients generally desire the opportunity to take
a potentially effective drug. Patients are likely to benefit from
the regular monitoring provided during clinical trials, but their
Table 1 – Results of a keypad voting survey of cancer
advocates, 2005
Survey item Response (%)
Are you aware of any cancer drugs that are
not available in your country but are available in others?
Yes 54
No 46
If yes, why is the drug not available?
The drug(s) are not licensed in my country 39
The public health authority will
not reimburse the drug(s)
56
Physicians will not prescribe the drug 0
Do not know 5
Do you know of anyone who has been refused
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